Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Burke

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
American Journal of Obstetrics & Gynecology MFM|October 10, 2022
Immediate postpartum care in low- and middle-income countries: A gap in healthcare quality research and practiceEmma Clarke-Deelder, Kennedy Opondo, Monica Oguttu, et al.
Cancers|February 25, 2022
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up DataVamsidhar Velcheti, Xiaohan Hu, Yeran Li, et al.
World Journal of Surgery|June 13, 2015
A Safe-Anesthesia Innovation for Emergency and Life-Improving Surgeries When no Anesthetist is Available: A Descriptive Review of 193 Consecutive SurgeriesThomas Burke, Yogeeta Manglani, Zaid Altawil, et al.
JCO Clinical Cancer Informatics|August 20, 2021
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Xiaoyun Nicole Li, Thomas Burke, et al.
BMJ Open|October 5, 2022
Non-anaesthetist-administered ketamine for emergency caesarean section in Kenya: cost-effectiveness analysisStephen Charles Resch, Sebastian Suarez, Moshood Olanrewaju Omotayo, et al.
Journal of Medical Economics|August 30, 2016
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United StatesMin Huang, Yanyan Lou, James Pellissier, et al.
Pharmacoeconomics|June 17, 2017
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United StatesMin Huang, Yanyan Lou, James Pellissier, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|January 30, 2010
A protocol for patients with cardiovascular implantable devices undergoing magnetic resonance imaging (MRI): should defibrillation threshold testing be performed post-(MRI)Peter Thomas Burke, Hamid Ghanbari, Patrick B Alexander, et al.
Cancer Chemotherapy and Pharmacology|November 16, 2007
In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell linesMarisa A Navo, Judith A Smith, Anjali Gaikwad, et al.
Blood Pressure. Supplement|January 25, 2006
Characteristics of blood-pressure control in treated hypertensive patients in CroatiaDinko Vitezić, Thomas Burke, Jasenka Mrsić-Pelcić, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
American Journal of Obstetrics & Gynecology MFM|October 10, 2022
Immediate postpartum care in low- and middle-income countries: A gap in healthcare quality research and practiceEmma Clarke-Deelder, Kennedy Opondo, Monica Oguttu, et al.
Cancers|February 25, 2022
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up DataVamsidhar Velcheti, Xiaohan Hu, Yeran Li, et al.
World Journal of Surgery|June 13, 2015
A Safe-Anesthesia Innovation for Emergency and Life-Improving Surgeries When no Anesthetist is Available: A Descriptive Review of 193 Consecutive SurgeriesThomas Burke, Yogeeta Manglani, Zaid Altawil, et al.
JCO Clinical Cancer Informatics|August 20, 2021
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Xiaoyun Nicole Li, Thomas Burke, et al.
BMJ Open|October 5, 2022
Non-anaesthetist-administered ketamine for emergency caesarean section in Kenya: cost-effectiveness analysisStephen Charles Resch, Sebastian Suarez, Moshood Olanrewaju Omotayo, et al.
Journal of Medical Economics|August 30, 2016
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United StatesMin Huang, Yanyan Lou, James Pellissier, et al.
Pharmacoeconomics|June 17, 2017
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United StatesMin Huang, Yanyan Lou, James Pellissier, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|January 30, 2010
A protocol for patients with cardiovascular implantable devices undergoing magnetic resonance imaging (MRI): should defibrillation threshold testing be performed post-(MRI)Peter Thomas Burke, Hamid Ghanbari, Patrick B Alexander, et al.
Cancer Chemotherapy and Pharmacology|November 16, 2007
In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell linesMarisa A Navo, Judith A Smith, Anjali Gaikwad, et al.
Blood Pressure. Supplement|January 25, 2006
Characteristics of blood-pressure control in treated hypertensive patients in CroatiaDinko Vitezić, Thomas Burke, Jasenka Mrsić-Pelcić, et al.
Pageof 11